This site is intended only for the use of UK Healthcare Professionals

Hypoallergenicity of a whey-based, extensively hydrolysed infant formula prepared with non porcine enzymes

Cows' Milk Allergy

31/03/2021

Nowak-Wegrzyn A, Czerkies L, Kuslys M, Nutten S, Simons PJ, Collins B and Heine RG.
Allergy 2019 Mar 21. doi: 10.1111/all.13780. Letter to the editor. Epub ahead of print

Objective

To characterize the peptide profile of a whey-based, extensively hydrolysed formula (eHF) prepared with a non porcine enzyme blend, and to assess whether it meets the hypoallergenicity criteria of the American Academy of Pediatrics (AAP).

Background

In the majority of formula‐fed infants with cows’ milk allergy (CMA), an eHF is considered the first‐line choice of formula. The manufacturing process for eHF traditionally involves the use of porcine pancreatic enzymes for the protein hydrolysis. However, these may not be considered suitable for religious (e.g. halal or kosher diet) or cultural (e.g. strict vegetarian diet) reasons. The AAP defines an eHF to be “hypoallergenic” if at least 90% of infants with CMA tolerate it under double‐blind, placebo‐controlled conditions (DBPCFC).

Materials and Methods

The Test formula was a whey‐based eHF (Althéra^®, Nestlé Health Science, Vevey, Switzerland) prepared with a microbial and plant‐derived, non porcine enzyme blend.
The Control formula was a marketed whey‐based eHF manufactured using porcine pancreatic enzymes (Althéra®, Nestlé Health Science, Vevey, Switzerland).
Peptide molecular weight (MW) distribution, residual milk allergen content and β-lactoglobulin (BLG) in vitro allergenicity were tested.
Hypoallergenicity and safety were clinically assessed through double-blind placebo-controlled food challenges (DBPCFC).
79 infants and children with CMA were enrolled and underwent the DBPCFC with both formulas in randomised order.
Hypoallergenicity was accepted if the exact 96.5% lower bound for the proportion of subjects without allergic reactions was at least 90% for the modified intention-to-treat (mITT) and per-protocol (PP) analysis populations.
If a subject successfully passed both DBPCFC sessions, a 1‐week open challenge with the Test formula was performed.

Results

Minor differences in the MW distribution were observed. No caseins, no intact milk proteins and only trace amounts of BLG were identified and in vitro tests did not demonstrate any residual BLG allergenicity.
Ten subjects were excluded due to inconclusive DBPCFC (<100 ml consumed).
The mITT analysis was performed based on 69 subjects (mean age 3.2 ± 2.22 years).
In the mITT cohort, 66/67 subjects (98.5%; lower bound 92.5%) tolerated the Test formula, while 67/69 (97.1%; lower bound 90.5%) tolerated the Control formula.
For the PP analysis, three patients were excluded due to protocol deviations.
Of the remaining 66 subjects (mean age 3.3 ± 2.21 years), 65 (98.5%, lower bound 92.4%) tolerated the Test formula, and 64 (97.0%, lower bound 90.1%) tolerated the Control formula.
Sixty‐five subjects completed the open‐label home challenge with Test formula.
There were no significant adverse clinical reactions.

Conclusion

Althéra^® prepared with non porcine enzymes was tolerated by at least 90% of children with CMA and meets the AAP hypoallergenicity criteria. Minor differences between Test and Control formulas regarding the MW distribution of peptides and residual BLG content did not translate into differences in clinical or in vitro allergenicity.

These findings confirm the hypoallergenicity and suitability of Althéra^® prepared with non porcine enzymes for the dietary management of CMA in infants and young children.

IMPORTANT NOTICE: Mothers should be encouraged to continue breastfeeding even when their infants have CMA. This usually requires qualified dietary counselling to completely exclude all sources of cows’ milk protein from the mother’s diet. If a decision to use a special formula intended for infants is taken, it is important to give instructions on correct preparation methods, emphasising that unboiled water, unsterilised bottles or incorrect dilution can all lead to illness. Formula for special medical purposes intended for infants must be used under medical supervision. © 2019 Nestlé. All rights reserved. Unless otherwise noted, all trademarks are owned by Société des Produits Nestlé SA. Study Summary prepared by Nestlé Health Science.

IMPORTANT NOTICE: Mothers should be encouraged to continue breastfeeding even when their infants have cows’ milk protein allergy. This usually requires qualified dietary counselling to completely exclude all sources of cows’ milk protein from the mothers’ diet. If a decision to use a special formula intended for infants is taken, it is important to give instructions on correct preparation methods, emphasising that unboiled water, unsterilised bottles or incorrect dilution can all lead to illness. Formula for special medical purposes intended for infants must be used under medical supervision.

Other content you might be interested in

Cow’s Milk Allergy in Primary Care

This webinar, hosted by Dr. Helen Evans-Howells, focuses on recognising and managing cow’s milk protein allergy (CMPA) in primary care. It offers an overview of how to effectively work with patients who have CMPA in a community setting. Key learning points include the differences between allergies and intolerances, when to test for allergies and how to interpret results, and insights into the future of food allergies. The session concludes with an informative Q&A session.

SMA Althera and SMA Alfamino - Clinical Evidence Book

WHAT MAKES AN EFFECTIVE SPECIALIST CMA FORMULA? Very few eHFs and AAFs have been shown effective, both in terms of allergy and growth.6,7 At Nestlé Health Science, we set the highest standards for our CMA formulas, SMA® Althéra® and SMA® Alfamino®, ensuring both manufacturing excellence and robust clinical evidence to demonstrate: Proven hypoallergenicity According to guidelines, the gold standard is for hypoallergenic formulas to be tolerated by at least 90% of infants with proven CMA (with 95% confidence interval) in a clinical trial.1,3,6 Growth and development According to guidelines, the gold standard is for hypoallergenic formulas to demonstrate normal growth in a clinical trial, because whilst eHF and AAF nutritional profiles are governed by strict regulations,7,8 there are still significant compositional differences between brands.5 REFERENCES: 1. Luyt D et al. Clin Exp Allergy 2014; 44: 642–672. 2. Grimshaw K et al. Clin Transl Allergy 2016; 6: 1. 3. Koletzko S et al. JPGN 2012; 55(2): 221–229. 4. Muraro A et al. Allergy 2014; 69(5): 590–601. 5. Meyer R et al. EMJ Allergy and Immunol. 2017; 2(1): 46–51. 6. Chauveau, A. et al. Pediatr Allergy Immunol. 2016; 27(5): 541–543. 7. Commission Delegated regulation (EU) 2016/128. 8. Commission directive 1999/21/EC

Diagnosing and Managing Cows' Milk Allergy

The aim of this webinar is to aid primary care individuals in the diagnosis and management of cows' milk protein allergy. Evidence suggests that it can take an average of 10 weeks and 4 visits to a healthcare professional to get a diagnosis of cows' milk allergy (CMA).1

Could I recommend a carer adding anything to the formula to make it taste better?

Kate discusses how adding flavours isn’t recommended - she further discusses how formulas containing lactose can taste better and therefore may be tolerated better.

Are there any vitamins or minerals I should be prescribing?

Helen discusses the vitamins and minerals needed with both breastfed infants and formula fed infants both with or with cows’ milk allergy.

The dietary management of Cows' Milk Allergy in Primary Care

A webinar explaining the dietary management of Cows’ Milk Allergy in primary care.

Cows’ Milk Allergy Weaning Guide

The weaning guide contains recipes developed with leading dietitians from across the UK to help your patients' carers prepare milk-free recipes. The weaning guide can help give them confidence, that as their child grows, family meals can be adapted to make them suitable for CMA.

Allergy tests to diagnose cows’ milk protein allergy

Professor Antonella Muraro, Paediatric Allergist, discusses the tests available to help support diagnosing CMA in infants. Filmed 2017.

Weaning with cows’ milk allergy: what does this mean in practice?

Rachel DeBoer, specialist paediatric allergy dietitian, discusses the challenges faced when weaning (complementary feeding) infants with CMA. Filmed in May 2017.

Practical tips for managing feeding aversions in the allergic child

Food allergies can have an impact on eating habits and food intake. This includes CMA where feeding difficulties has been described as a possible feature. Dr Polly James, paediatric clinical psychologist, discusses practical tips for managing feeding aversions in the allergic child. Filmed in May 2017

The Benefits of Human Milk Oligosaccharides (HMO) on Immunity

Human milk contains bioactive components that confer protection on the newborn. These include complex carbohydrates called Human Milk Oligosaccharides (HMO). Research is revealing the full extent of the beneficial properties of HMOs.

Lactose Intolerance: Common Misunderstandings

Lactose intolerance is one of the more common forms of food intolerance and is often confused with cows' milk allergy. This video explains the differences in both symptoms, diagnosis and treatment. It also explains the different types of lactose intolerance.